Related Experiment Videos
Thrombocytosis--report of a case
1Department of Internal Medicine and Haematology, Medical College Hospital, Trivandrum-695 011.
The Journal of the Association of Physicians of India
|March 29, 2001
Summary
Thrombocytosis, a condition of high platelet count, was effectively managed with anagrelide in a chronic myeloid leukemia patient unresponsive to hydroxyurea. Anagrelide offers a promising new treatment for thrombocytosis associated with leukemia.
Area of Science:
- Hematology
- Oncology
Background:
- Thrombocytosis is a condition characterized by elevated platelet counts.
- Standard treatments for thrombocytosis include hydroxyurea, alkylating agents, and interferon alpha.
Observation:
- A case of chronic myeloid leukemia (CML) with thrombocytosis is presented.
- The patient did not respond adequately to hydroxyurea therapy.
Findings:
- Addition of anagrelide to the treatment regimen controlled the thrombocytosis.
- Anagrelide demonstrated efficacy as a platelet-reducing agent with a favorable side effect profile.
Implications:
- Anagrelide may represent a significant therapeutic option for managing thrombocytosis in CML.
- This drug could become a primary treatment for essential thrombocytosis and CML-associated thrombocytosis in the future.